Showing results (81-90 of 108) with videos related to
Sort By:
Pageof 11
Journal for Immunotherapy of Cancer|May 21, 2021
INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2)Melissa Bersanelli, Diana Giannarelli, Ugo De Giorgi, et al.Immunotherapy|October 18, 2018
INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa studyMelissa Bersanelli, Diana Giannarelli, Paola Castrignanò, et al.Iscience|October 20, 2023
Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysisShobana Anpalakhan, Alessio Signori, Alessio Cortellini, et al.The Oncologist|December 24, 2025
Adjuvant atezolizumab in surgically resected NSCLC patients with PD-L1 expression ≥50%: real-world data from the italian ATLAS registryFrancesco Passiglia, Maria Lucia Reale, Giulia Pasello, et al.Journal for Immunotherapy of Cancer|October 20, 2020
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validationAlessio Cortellini, Biagio Ricciuti, Marcello Tiseo, et al.Journal of Hematology & Oncology|January 22, 2022
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene statusAlessio Cortellini, Raffaele Giusti, Marco Filetti, et al.European Journal of Cancer (Oxford, England : 1990)|June 15, 2022
Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancerDavid J Pinato, Daniela Ferrante, Juan Aguilar-Company, et al.Lung Cancer (Amsterdam, Netherlands)|November 1, 2020
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY studyMelissa Bersanelli, Sebastiano Buti, Diana Giannarelli, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2023
Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast CancerMarco Tagliamento, Alessandra Gennari, Matteo Lambertini, et al.European Journal of Cancer (Oxford, England : 1990)|March 15, 2021
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world studyAlessio Cortellini, Katia Cannita, Marcello Tiseo, et al.Pageof 11